---
title: Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
nct_id: NCT03161366
overall_status: COMPLETED
phase: PHASE3
sponsor: Epicentre
study_type: INTERVENTIONAL
primary_condition: Ebola Virus Disease
countries: Democratic Republic of the Congo, Uganda
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03161366.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03161366"
ct_last_update_post_date: 2018-12-19
last_seen_at: "2026-05-12T06:22:34.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

**Official Title:** An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP

**NCT ID:** [NCT03161366](https://clinicaltrials.gov/study/NCT03161366)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 500
- **Lead Sponsor:** Epicentre
- **Collaborators:** Medecins Sans Frontieres, Netherlands
- **Conditions:** Ebola Virus Disease
- **Start Date:** 2018-05-28
- **Completion Date:** 2018-11-30
- **CT.gov Last Update:** 2018-12-19

## Brief Summary

Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.

## Detailed Description

Ebola Virus Disease remains ill-known by populations, creating fear and mistrust, is highly contagious, requiring strict isolation measures and with only supportive therapy available that has limited impact on case-fatality which remains high (30 -80%).1 Among vaccines in development, the rVSVΔG-ZEBOV-GP vaccine has given the most promising results in terms of efficacy and safety having been evaluated now in more than 10,000 individuals.

Ring vaccination is a known strategy to control epidemics with specific transmission chains and has been successfully implemented to eradicate smallpox. Ring vaccination enhances standard public health measures of contact tracing, isolation, and community engagement and could be effective when such measures are in place. Building on the interim results of the Ebola ça Suffit trial, there is a need for continued access to a vaccine of which available results suggest that it is safe and likely efficacious against EVD. Although only isolated cases have been reported in Guinea, Sierra Leone and Liberia in 2016, 10 the risk of resurgence or of continued isolated cases in West Africa remains. Moreover, a new outbreak with Ebola Zaïre could start any moment in any of the countries where previous outbreaks occurred as in for example Democratic Republic of Congo and Uganda.

However, the unusual design of the ring trial and the decision to abandon the control group because of strong evidence that the vaccine prevented disease means there may not be enough data to ensure approval from regulatory agencies. Therefore, additional information is still required to consolidate knowledge on the rVSVΔG-ZEBOV-GP vaccine to support regulatory approval and licensure for future access. Additional information is also needed on ring vaccination and contextual adaptations to this approach to ensure its feasibility and effectiveness in the control of Ebola outbreaks in potentially diverse contexts.

## Eligibility

- **Minimum age:** 1 Year
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Individuals aged 6 years or older will be enrolled in the study if they are a contact or contact of contact of a laboratory-confirmed Ebola virus disease case. Children aged between 1 and 6 years may also be enrolled in the study in case there is a confirmed contact with a laboratory-confirmed Ebola patient
* willing to accept weekly visits
* intending to remain in the study area for three months
* providing informed consent, and where applicable, assent

Exclusion Criteria:

* history of EVD (self-report or laboratory confirmed)
* history of having received other investigational research agents in the previous 28 days
* history of anaphylaxis to a vaccine or vaccine component (self-report)
* severe illness that makes the person bed-bound or requiring hospitalization at the time of the vaccination
* severe immunocompromised status
* history of having received immunosuppressant therapies that would substantially interfere with the mode of action of the Ebola vaccine in the previous 6 months
* unwilling to accept weekly visits
* not intending to remain in the study area for three months
* informed consent or assent not provided
* any other condition in which, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, or impair the subject or caregiver's ability to give informed consent, and where applicable, assent.
* fever above 38°C
* previous receipt of rVSVΔG-ZEBOV-GP in the last 3 years or at being part of another Ebola vaccine clinical trial.
```

## Arms

- **Single arm** (EXPERIMENTAL) — Vaccination of contacts and contacts of contacts of a confirmed Ebola Zaire case with one dose of rVSVΔG-ZEBOV-GP (≥ 2x10\^7 PFU)

## Interventions

- **rVSVΔG-ZEBOV-GP** (BIOLOGICAL) — Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case

## Primary Outcomes

- **Cumulative incidence** _(time frame: 84 days after vaccination)_ — Occurrence of Ebola Zaire cases amongst contacts and contacts of contacts

## Secondary Outcomes

- **Assessment of Adverse and Serious Adverse Events** _(time frame: 84 days after vaccination)_

## Locations (2)

- Médecins Sans Frontières, Kinshasa, Democratic Republic of the Congo
- Epicentre, Mbarara, Uganda

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.médecins sans frontières|kinshasa||democratic republic of the congo` — added _(2026-05-12)_
- `locations.epicentre|mbarara||uganda` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03161366.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03161366*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*